Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3351390 | 0.84 | BACE1 (0.38) | ADRB1BACE1CTSDF2 | |
| SCHEMBL3350430 | 0.83 | BACE1 (0.40) | ADRB1BACE1CTSD | |
| SCHEMBL3352638 | 0.82 | BACE1 (0.44) | ADRB1BACE1CTSD | |
| SCHEMBL6039329 | 0.81 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL14163606 | 0.80 | BACE1 (0.42) | ADRA2AADRA2BADRA2CADRA1ASLC6A2 | |
| SCHEMBL3349058 | 0.79 | CSNK1E (0.40) | ADRB1BACE1CTSD | |
| SCHEMBL3346966 | 0.79 | LAP3 (0.39) | ADRB1BACE1CTSD | |
| SCHEMBL13814727 | 0.79 | IDO1 (0.36) | ADRA2AADRA2BADRA2CADRA1AADRB1 | |
| SCHEMBL4823652 | 0.79 | IDO1 (0.36) | ADRB1 | |
| SCHEMBL3355984 | 0.78 | ANPEP (0.39) | ADRB1BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | claimed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | HNMT, PNMT, BHMT | ADRA2A 629/4885ADRA2B 1303/4885ADRA2C 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.